The role of glucocorticoid action in the pathophysiology of the Metabolic Syndrome

被引:219
作者
Wang M. [1 ]
机构
[1] Department of Metabolic Disorders, Amgen Inc., Thousand Oaks, CA
关键词
Insulin Resistance; Cortisol; Metabolic Syndrome; Corticosterone; Carbenoxolone;
D O I
10.1186/1743-7075-2-3
中图分类号
学科分类号
摘要
Glucocorticoids are stress hormones that modulate a large number of physiological actions involved in metabolic, inflammatory, cardiovascular and behavioral processes. The molecular mechanisms and the physiological effects of glucocorticoids have been extensively studied. However, the involvement of glucocorticoid action in the etiology of the Metabolic Syndrome has not been well appreciated. Recently, accumulating clinical evidence and animal genetics studies have attracted growing interest in the role of glucocorticoid action in obesity and insulin resistance. This review will discuss the metabolic effects in the context of glucocorticoid metabolism and establish the association of glucocorticoid action with the features of the Metabolic Syndrome, especially obesity and insulin resistance. Special discussions will be focused on corticosteroid-binding globulin and 11β-hydroxysteroid dehydrogenase type 1, two proteins that mediate glucocorticoid action and have been implicated in the Metabolic Syndrome. Due to the complexities of the glucocorticoid biology and the Metabolic Syndrome and limited space, this review is only intended to provide a general link between the two areas with broad rather than in-depth discussions of clinical, pharmacological and genetic findings. © 2005 Wang; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 148 条
  • [1] Reaven G.M., Role of insulin resistance in human disease. Banting lecture, Diabetes, 37, 12, pp. 1595-1607, (1988)
  • [2] Reaven G.M., Insulin resistance, hyperinsulinemia, hypertriglyceridemia, and hypertension. Parallels between human disease and rodent models, Diabetes Care, 14, 3, pp. 195-202, (1991)
  • [3] DeFronzo R.A., Ferrannini E., Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease, Diabetes Care, 14, 3, pp. 173-194, (1991)
  • [4] Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report, Circulation, 106, pp. 3143-3421, (2002)
  • [5] Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications: Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus, (1999)
  • [6] Alberti K.G., Zimmet P.Z., Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation, Diabet Med, 15, 7, pp. 539-553, (1998)
  • [7] Grundy S.M., Brewer Jr. H.B., Cleeman J.I., Smith Jr. S.C., Lenfant C., Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition, Circulation, 109, 3, pp. 433-438, (2004)
  • [8] Ford E.S., Giles W.H., Dietz W.H., Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey, JAMA, 287, 3, pp. 356-359, (2002)
  • [9] Trevisan M., Liu J., Bahsas F.B., Menotti A., Syndrome X and mortality: A population-based study, Am J Epidemiol, 148, 10, pp. 958-966, (1998)
  • [10] Isomaa B., Almgren P., Tuomi T., Forsen B., Lahti K., Nissen M., Taskinen M.R., Groop L., Cardiovascular morbidity and mortality associated with the metabolic syndrome, Diabetes Care, 24, 4, pp. 683-689, (2001)